Skip to main content
. 2016 Jun 17;6:28217. doi: 10.1038/srep28217

Figure 2. BRCA1-mutant breast cancer cell lines are resistant to MEK1/2 inhibitors.

Figure 2

(a) Sensitivity of BRCA1-mutant (red) and BRCA1-wild-type (blue) cell lines to MEK1/2 and Akt inhibitors was re-tested in 96-well plates using CellTiter-Blue fluorescent metabolic assay. Each data point represents an average of four replicas. Non-linear regression curves were calculated using GraphPad Prism. (b) to When compared with BRCA1-wild-type cell lines (on the right), BRCA1-mutant cell lines (on the left) have increased phosphorylation of AKT (except SUM1315MO2) and CHK2 kinase as revealed with a Human Phospho-Kinase Antibody Array. Each kinase is tested in duplicates. Spots corresponding to AKT phosphorylated at S473 and Chk2 phosphorylated at T68 are highlighted with red and yellow rectangles, respectively. Spot coordinates are marked along the left and the top edges of each membrane. (c) List of all targets of the Human Phospho-Kinase Antibody Array and their coordinates.